Literature DB >> 1438983

Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor.

G N Swanson1, J M Hanesworth, M F Sardinia, J K Coleman, J W Wright, K L Hall, A V Miller-Wing, J W Stobb, V I Cook, E C Harding.   

Abstract

We report here the discovery of a unique and novel angiotensin binding site and peptide system based upon the C-terminal 3-8 hexapeptide fragment of angiotensin II (NH3(+)-Val-Tyr-Ile-His-Pro-Phe-COO-) (AII(3-8) (AIV)). This fragment binds saturably, reversibly, specifically, and with high affinity to membrane-binding sites in a variety of tissues and from many species. The binding site is pharmacologically distinct from the classic angiotensin receptors (AT1 or AT2) displaying low affinity for the known agonists (AII and AIII) and antagonist (Sar1,Ile8-AII). Although a definitive function has not been assigned to this system in many of the tissues in which it resides, AIV's interaction with endothelial cells may involve a role in endothelial cell-dependent vasodilation. Consequent to this action, AIV is a potent stimulator of renal cortical blood flow.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1438983     DOI: 10.1016/0167-0115(92)90527-2

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  29 in total

1.  Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning.

Authors:  J W Wright; L Stubley; E S Pederson; E A Kramár; J M Hanesworth; J W Harding
Journal:  J Neurosci       Date:  1999-05-15       Impact factor: 6.167

Review 2.  The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases.

Authors:  John W Wright; Joseph W Harding
Journal:  Pflugers Arch       Date:  2012-04-26       Impact factor: 3.657

Review 3.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

4.  Angiotensin IV is induced in experimental autoimmune encephalomyelitis but fails to influence the disease.

Authors:  Arndt Manzel; Oliver Domenig; Bjoern Ambrosius; Agnes Kovacs; Johannes Stegbauer; Marko Poglitsch; Dominik N Mueller; Ralf Gold; Ralf A Linker
Journal:  J Neuroimmune Pharmacol       Date:  2014-05-23       Impact factor: 4.147

Review 5.  Molecular biology of angiotensin receptors and their role in human cardiovascular disease.

Authors:  V Regitz-Zagrosek; M Neuss; J Holzmeister; C Warnecke; E Fleck
Journal:  J Mol Med (Berl)       Date:  1996-05       Impact factor: 4.599

6.  Angiotensin IV elevates oxytocin levels in the rat amygdala and produces anxiolytic-like activity through subsequent oxytocin receptor activation.

Authors:  Chad E Beyer; Jason M Dwyer; Brian J Platt; Sarah Neal; Bin Luo; Huai-Ping Ling; Qian Lin; Robert J Mark; Sharon Rosenzweig-Lipson; Lee E Schechter
Journal:  Psychopharmacology (Berl)       Date:  2010-03-12       Impact factor: 4.530

Review 7.  Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review.

Authors:  Bart Stragier; Dimitri De Bundel; Sophie Sarre; Ilse Smolders; Georges Vauquelin; Alain Dupont; Yvette Michotte; Patrick Vanderheyden
Journal:  Heart Fail Rev       Date:  2007-11-08       Impact factor: 4.214

8.  Oxidative stress-mediated effects of angiotensin II in the cardiovascular system.

Authors:  Hairuo Wen; Judith K Gwathmey; Lai-Hua Xie
Journal:  World J Hypertens       Date:  2012-08-23

9.  Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV.

Authors:  D M Kerins; Q Hao; D E Vaughan
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

10.  The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor.

Authors:  B J Yamamoto; P D Elias; J A Masino; B D Hudson; A T McCoy; Z J Anderson; M D Varnum; M F Sardinia; J W Wright; J W Harding
Journal:  J Pharmacol Exp Ther       Date:  2010-01-19       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.